Apomorphine HCl CAS: 41372-20-7 Apomorphine HCl is a versatile API commonly associated with treating Parkinson’s disease. When those who suffer from Parkinson’s have difficulty walking or speaking, they can take apomorphine as a means to gain control over their movements. It can’t prevent the episodes, but it can make it easier to handle the symptoms[…]
Apomorphine HCl: A Promising Drug to Help Parkinson’s Patients
Anti-Parkinsons Tags: Apomorphine Nov 14, 2018
Ropinirole Therapy Helps Patients with RLS
Anti-Parkinsons, Drug Research & Development API Tags: Restless Legs Syndrome Jul 27, 2015
Known as Restless Legs Syndrome, or RLS, this disruptive condition occurs in roughly 7% of the population worldwide. While patients older than age 65 are most commonly diagnosed, there are children who experience RLS as well. With approximately 10% of children experiencing a sleep disorder globally, the diagnosis of RLS in the adolescent population is[…]
Droxidopa Approved for Parkinson’s-Related Hypotension
Anti-Parkinsons, Drug Research & Development API, FDA Approved 2014 Tags: hypertension Feb 28, 2014
The FDA recently approved Droxidopa, known as the brand name Northera, to treat neurogenic orthostatic hypotension, which is a common complication of Parkinson’s disease. Neurogenic orthostatic hypotension or NOH is an uncommon but dangerous drop in blood pressure that presents upon standing. Patients with NOH exhibit symptoms like severe dizziness, a faint feeling, weakness, fatigue[…]
Pimavanserin a Promising Treatment for Parkinson’s Psychosis
Anti-Parkinsons, Antipsychotic, Drug Research & Development API Tags: serotonin Dec 06, 2013
Encouraging news from The Lancet was published in mid-November 2013 regarding the use of Pimavanserin to alleviate Parkinson’s Psychosis. Data from a successful phase 3 trial was revealed and strongly touted the use of Pimavanserin for psychotic symptoms as related to Parkinson’s disease. Pimavanserin is effectual at blocking serotonin 5-HT2A receptors, which are often associated[…]
Could Gabapentin Have Helped Kate Middleton- and Can it Help All Women with Hyperemesis Gravidarum?
Analgesic, Anti-Parkinsons, Bulk Active Ingredient, Drug Research & Development API, OTC and Compounding Product, Patent Expiration 2017 Tags: epilepsy Mar 05, 2013
Gabapentin, also known as Neurontin, has long been a stable and effective treatment for patients who experience seizures, certain forms of epilepsy and pain from shingles. New research has indicated another effectual use for Gabapentin, CAS 60142-96-3, as a treatment to help combat symptoms of severe morning sickness. Known as hyperemesis gravidarum, this extreme form[…]
Patients with Restless Legs Syndrome Find Relief with Gabapentin Enacarbil
Analgesic, Anti-Parkinsons, Cardiovascular Agent, Drug Research & Development API Tags: Restless Legs Syndrome Aug 17, 2012
Gabapentin Enacarbil, CAS number 478296-72-9, is also known as Horizant, which is marketed by GlaxoSmithKline. As a medication approved by the FDA to treat Moderate-to-Severe Primary Restless Legs Syndrome {RLS}, this drug is a welcome relief for patients who suffer from this frustrating neurological condition. RLS is more likely to occur in women, and includes[…]
Levodopa Is a Major Player in New Research for Parkinson's Disease
Anti-Parkinsons, Drug Research & Development API, TEVA API Tags: EuropeRestless Legs Syndrome Jun 11, 2012
Levodopa is typically prescribed alongside carbidopa to treat Parkinson’s disease. Brand names Sinemet and Sinemet CR are comprised of levodopa and carbidopa, and systemic levodopa can be found under the names Dopar and Larodopa. Classified as a dopaminergic antiparkinsonism agent, levodopa is also used to treat Periodic Limb Movement Disorder and Restless Legs Syndrome when[…]
